This content is machine translated ESC Congress 2017, Barcelona Prevention of atrial fibrillation and complications The epidemic scale and serious complications make atrial fibrillation a major threat to cardiovascular health. In addition to vitamin K antagonists, four new oral anticoagulants (NOAKs) are available for stroke…
View Post 5 min This content is machine translated Coagulation tests Methods of choice for direct oral anticoagulants. DOAK affect routine coagulation tests to an extent that varies depending on the substance, the time of measurement, and the test system used. However, a statement about the strength of…
View Post 6 min This content is machine translated Chronic heart failure and stroke prevention in VHF. Optimized treatment regimens and new therapeutic options The December lecture series in Zurich featured a presentation by PD Georg Noll, MD, on the treatment of chronic heart failure, in which he shared his practical clinical experience. The…
View Post 7 min This content is machine translated Cardiology Highlights 2013 New practice-relevant European guidelines What news did the 2013 European Congress of Cardiology in Amsterdam bring? Discussed were not only practice-relevant guidelines, but also the current trends regarding lifestyle modifications. Furthermore, studies on the…
View Post 4 min This content is machine translated New anticoagulants Questions of practical application are to be clarified The new anticoagulants rivaroxaban, apixaban, and dabigatran promise several benefits, but are not suitable for all patient populations. Various questions arise in primary care practice, which were discussed at this…
View Post 6 min This content is machine translated Current overview New Anticoagulants in Prevention and Therapy of Thromboembolism The standard treatment for acute venous thromboembolism currently includes parenteral heparin administration, overlapping with the administration of a vitamin K antagonist (VKA). New oral anticoagulants (NOACs) and VKAs show different…
View Post 12 min This content is machine translated Atrial fibrillation and secondary prevention after stroke Status of the new anticoagulants In primary and secondary prevention in patients with atrial fibrillation (AF), after a long period of monopoly of vitamin K antagonists (VKA), new agents such as dabigatran, rivaroxaban, and apixaban…
